MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clml.2022.04.012

Медицинская библиотека · Clinical lymphoma, myeloma & leukemia · 2022

Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting.

Nasta Sunita D, Hughes Mitchell E, Namoglu Esin C, Garfall Alfred, DiFilippo Heather, Ballard Hatcher J, Barta Stefan K, Chong Elise A, Frey Noelle V, Gerson James N, Landsburg Daniel J, Ruella Marco, Schuster Stephen J, Svoboda Jakub, Weber Elizabeth, Porter David L

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

INTRODUCTION

Chimeric antigen receptor T-cell therapy (CAR T) is a revolutionary adoptive immunotherapy approach in lymphoma; however, substantial resources are necessary for administration and care of these patients. Our institution has administered tisagenlecleucel primarily in an outpatient setting, and here we report our clinical outcomes.

PATIENTS AND

METHODS

We conducted a single institution, retrospective study investigating outcomes of adult lymphoma patients treated with commercial tisagenlecleucel between 10/2017 and 12/2020. We analyzed patient characteristics and outcomes of efficacy and safety including overall response rate, progression-free survival, overall survival and cytokine-release syndrome, neurotoxicity, and hospitalizations.

RESULTS

Seventy-two patients with relapsed or refractory non-Hodgkin lymphoma (NHL) who received commercial tisagenlecleucel were identified; 68 (94.4%) patients received outpatient tisagenlecleucel. The overall response rate was 43% with a complete response observed in 25 patients (34.7%). At a median follow-up of 9.1 months, the median progression-free survival was 3.3 months. Grade 3-4 cytokine release syndrome was not observed in the study group and two patients had grade 3-4 neurotoxicity. Twenty-six patients (36.1%) were admitted within 30 days after infusion with a median length of stay of 5 days. Fourteen patients (19.4%) were admitted within 72 hours of infusion. No patient died of CAR T cell-related toxicity.

CONCLUSION

Our experience affirms treatment with tisagenlecleucel in the outpatient setting is safe and feasible with close supervision and adequate institutional experience. After infusion, adverse events were manageable and the majority of patients did not require hospitalization.

Для цитирования: Nasta Sunita D, Hughes Mitchell E, Namoglu Esin C, Garfall Alfred, DiFilippo Heather, Ballard Hatcher J, Barta Stefan K, Chong Elise A, Frey Noelle V, Gerson James N, Landsburg Daniel J, Ruella Marco, Schuster Stephen J, Svoboda Jakub, Weber Elizabeth, Porter David L. Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting.. Clinical lymphoma, myeloma & leukemia. 2022. DOI: 10.1016/j.clml.2022.04.012.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.